Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$3.5 - $6.9 $135,646 - $267,416
-38,756 Reduced 27.22%
103,644 $42,000
Q3 2021

Nov 12, 2021

BUY
$8.2 - $12.4 $1.17 Million - $1.77 Million
142,400 New
142,400 $132,000

About Cellectar Biosciences, Inc.


  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $12.5M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Franklin Resources Inc Portfolio

Follow Franklin Resources Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.